Enterococcus faecalis Agent for Pseudomonas aeruginosa Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pseudomonas aeruginosa infections pose a challenge due to natural resistance to certain antibiotics and the emergence of multidrug-resistant strains, particularly in immunocompromised patients, leading to opportunistic infections in hospitals and elderly care facilities.
Innovation Solution
A prophylactic and therapeutic agent comprising a bacterium from the genus Enterococcus, specifically Lactococcus Enterococcus faecalis EF-2001, which is administered orally to prevent and treat Pseudomonas aeruginosa infections, either in viable or killed form, with dosages ranging from 1×10^8 to 1×10^11 CFU/kg body weight, administered one to five times a day for seven or more days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat Pseudomonas aeruginosa infection, then bacterial infection can be controlled, but multidrug resistance develops and treatment effectiveness decreases
Solution Approach 1:
The patent uses Enterococcus faecalis as an intermediary organism to combat Pseudomonas aeruginosa infection. Instead of directly using antibiotics that face resistance issues, the Enterococcus bacterium acts as a mediator that produces substances (such as bacteriocins or competitive exclusion factors) that inhibit P. aeruginosa growth, thereby overcoming the multidrug resistance problem while maintaining treatment effectiveness
Solution Approach 2:
The patent changes the therapeutic parameter from chemical antibiotics to biological agents (Enterococcus faecalis). This parameter change allows the treatment to bypass traditional antibiotic resistance mechanisms by utilizing biological interactions such as competitive exclusion, production of inhibitory substances, or modulation of the host immune response, thereby restoring treatment effectiveness against multidrug-resistant strains
2Reliability
If Enterococcus faecalis is administered orally to prevent Pseudomonas aeruginosa infection, then infection prevention and treatment effectiveness are improved, but the mechanism of action and optimal dosage requirements need to be established
Solution Approach 1:
The Enterococcus faecalis strain is selected for its ability to self-colonize the gastrointestinal tract and provide protective effects without requiring complex external intervention. The bacterium naturally competes with P. aeruginosa for resources and space in the gut, and can self-produce inhibitory substances, reducing the need for complex monitoring and adjustment protocols
Solution Approach 2:
The patent employs prophylactic administration of Enterococcus faecalis before Pseudomonas aeruginosa infection occurs. By establishing the protective bacterium in advance in the gastrointestinal tract, the system creates a preemptive defense mechanism that prevents P. aeruginosa colonization, thereby simplifying the overall treatment approach compared to treating established infections
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agent effectively prevents and treats Pseudomonas aeruginosa infections by enhancing intestinal immunity and combating multidrug-resistant strains, as demonstrated by improved survival rates and reduced clinical symptoms in infected mice models.
Implementation Method 1
The agent effectively prevents and treats Pseudomonas aeruginosa infections by enhancing intestinal immunity
Implementation Method 2
combating multidrug-resistant strains, as demonstrated by improved survival rates and reduced clinical symptoms in infected mice models
Data Source
AI summary
Provided is a novel prophylactic and/or therapeutic agent for Pseudomonas aeruginosa infection. It was found that a bacterium belonging to the genus Enterococcus can prevent and/or treat Pseudomonas aeruginosa infection. The prophylactic and/or therapeutic agent for Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus. A medicine for prevention and/or treatment of Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus. A food for prevention and/or treatment of Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus.